Hereditary Hemorrhagic Telangiectasia: Pregnancy and Delivery-Specific Considerations and Outcomes
American Journal of Perinatology · 01.04.2025 · 42 (05) · 564-571
DOI: 10.1055/a-2419-9036 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Perinatology, erschienen am 01.04.2025. Verfasst von Virginia Y Watkins und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Duke University Hospital, Durham, North Carolina. Hauptthemen laut MEDLINE: Telangiectasia, Hereditary Hemorrhagic, Pregnancy Outcome. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Abstract (Originalsprache)
Prior studies have evaluated maternal outcomes in patients with hereditary hemorrhagic telangiectasia (HHT), yet pregnancy- and delivery-specific data remain limited. This study aims to evaluate pregnancy and delivery outcomes in patients with HHT. This retrospective cohort study used the Nationwide Readmissions Database to identify patients with HHT diagnosis on delivery between 2010 and 2021. The primary outcome was severe maternal morbidity (SMM). Secondary outcomes included nontransfusion SMM, preterm birth, stillbirth, prelabor rupture of membranes or preterm prelabor rupture of membranes, cesarean delivery, respiratory bleeding, cerebrovascular complications, patient disposition, and length of stay. Trends in the prevalence of HHT at delivery were assessed with logistic regression. Logistic regression analyses, adjusting for age, payer, zip code income, hospital size, and teaching status, were also used to produce adjusted relationships between HHT status and outcomes. The cohort of 21,698,861 delivered pregnancies corresponded to a national estimate of 44,325,599. Of those, 612 (national estimate: 1,265; 2.8 per 100,000) had a diagnosis of HHT. A steady rise in the HHT diagnosis rate during pregnancy from 2010 to 2021 (1.7 per 100,000 in 2010, 3.8 per 100,000 in 2021, p < 0.001 for trend) was seen. Patients with HHT were significantly more likely to experience SMM compared with patients without HHT (7.8 vs. 1.7%, adjusted relative risk [aRR]: 4.49 [95% confidence interval, CI: 3.06, 6.58]). Rates of preterm birth (14.2 vs. 8.5%, aRR: 1.57 [95% CI: 1.22, 2.03]), cesarean delivery (41.0 vs. 32.9%, aRR: 1.23 [95% CI: 1.07, 1.41]), respiratory bleeding (2.1 vs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Duke University Hospital, Durham, North Carolina.
- Department of Population Health Sciences, Duke University Hospital, Durham, North Carolina.
ORCID-Profile: Virginia Y Watkins, Amanda M Craig, Jerome J Federspiel
Förderung
- NICHD NIH HHS
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
Zitieren
APA
Watkins, V. Y., Estin, M. L., Craig, A. M., Dotters-Katz, S. K., & Federspiel, J. J. (2025). Hereditary Hemorrhagic Telangiectasia: Pregnancy and Delivery-Specific Considerations and Outcomes. American Journal of Perinatology, 42(05), 564-571. https://doi.org/10.1055/a-2419-9036
Vancouver
Watkins VY, Estin ML, Craig AM, Dotters-Katz SK, Federspiel JJ. Hereditary Hemorrhagic Telangiectasia: Pregnancy and Delivery-Specific Considerations and Outcomes. American Journal of Perinatology. 2025;42(05):564-571. doi:10.1055/a-2419-9036
BibTeX
@article{Watkins2025,
author = {Watkins, Virginia Y and Estin, Mira L and Craig, Amanda M and Dotters-Katz, Sarah K and Federspiel, Jerome J},
title = {Hereditary Hemorrhagic Telangiectasia: Pregnancy and Delivery-Specific Considerations and Outcomes},
journal = {American Journal of Perinatology},
year = {2025},
volume = {42},
number = {05},
pages = {564--571},
doi = {10.1055/a-2419-9036}
}
EUVIMED